Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class ...

Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

SYX-5219 offers first-in-class potential as an oral, disease-modifying anti-inflammatory therapy, targeting a critical enzyme that regulates cell metabolism called pyruvate kinase M2 (PKM2).

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission Novel mechanism of action suggests SYX-5219 has potential across broad range of inflammatory diseases ...

Liver fibrosis is a major global health concern, developing as a result of chronic liver diseases (CLDs) such as viral ...

Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China. (Y.E.L., S.L., Litao Wang, Y.D., L. Wu, H.C., T ...

Pathways such as Toll-Like Receptors (TLRs), Phosphoinositol-3 Kinase-Protein Kinase B-mammalian Target of Rapamycin (PI3K-Akt-mTOR), and Pyruvate Kinase M2-Hypoxia-inducible factor 1-alpha ...